SCHEMBL8174608

SCHEMBL8174608

CN(c1cccc(Cl)c1)c1cccc(Cn2cc(CC(=O)O)c3ccccc32)c1

nearest known ligand 0.80

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.80
ALDH1A1 P00352 4/20 0.80
SMN1; SMN2 Q16637 2/20 0.59
NPSR1 Q6W5P4 2/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
HTT P42858 2/20 0.54
HTR6 P50406 2/20 0.49
PPARG P37231 3/20 0.48
PPARD Q03181 3/20 0.48
PPARA Q07869 3/20 0.48
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
MCL1 Q07820 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CDC25A P30304 1/20 0.47
PLK1 P53350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8178966 0.95 LMNA (0.74) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8175034 0.93 LMNA (0.71) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL13931029 0.92 LMNA (0.69) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8180810 0.90 LMNA (0.68) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8172895 0.90 LMNA (0.68) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8188626 0.90 LMNA (0.67) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8181393 0.90 LMNA (0.67) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL6893171 0.89 LMNA (1.00) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8180735 0.89 LMNA (0.66) LMNAALDH1A1SMN1; SMN2NPSR1MEN1
SCHEMBL8180114 0.88 LMNA (0.63) LMNAALDH1A1SMN1; SMN2NPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS LMNA 2969/4885ALDH1A1 1836/4885SMN1; SMN2 2901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.